Acknowledgements
Blood Cancer, Leukemia, Cancer
BLOOD, BLOOD CANCER, LEUKEMIA, CANCER
We thank the patients and their families for making this study possible; the support by Blood Cancer UK under the Trials Acceleration Programme (TAP) and the Trial Steering Committee members T. Sommervaille, S. Ali and J. Lambert for study design, data collection, and analysis; C. Fielding, H. Matsubara, C. Bernardo-Castiñeira, A. Sommerschield and members of the S.M.-F. group for help and discussions; J. Carroll, B. Huntly, J. Li, and A.R. Green for critical advice and support; Cambridge NIHR BRC Cell Phenotyping Hub for technical assistance; D. Bexheti and R. Houghton (Cancer Research UK) for LC-MS/MS. Samples were provided by the Cambridge Blood and Stem Cell Biobank, which is supported by the Cambridge NIHR Biomedical Research Centre, Wellcome Trust - MRC Stem Cell Institute and the Cambridge Experimental Cancer Medicine Centre, UK. Z.F. was supported by CSC-Cambridge Trust Scholarship. T.M. was supported by NIHR Starter Grant for Clinical Lecturers (SGL018/1032). D.F. was supported by Associazione Italiana Ricerca sul Cancro (AIRC-Fellowship 20930 for Abroad) and scholarships from Società Italiana di Ematologia (SIE) and Associazione “Amici di Beat Leukemia Dr. Alessandro Cevenini ONLUS” and AIL Bologna ODV. H.R.B. and J.H. were supported by the Medical Research Council (MC_UU_00015/2). S.M.-F was supported by the National Health Service Blood and Transplant (United Kingdom). S.M.-F was supported by European Union’s Horizon 2020 research (ERC-2014-CoG-648765). S.M.-F was supported by MRC-AMED grant MR/V005421/1. S.M.-F was supported by a Programme Foundation Award (C61367/A26670) from Cancer Research UK. This research was funded in whole, or in part, by the Wellcome Trust 203151/Z/16/Z] and the UKRI Medical Research Council [MC_PC_17230]. For the purpose of open access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission.